Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the ...

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

An independent study, carried out by the University of Leeds on behalf of HSL Chairs, has revealed that sitting in the correct size chair can reduce blood pressure by 10% and heart rate by 6% as well ...